Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12470023 | 0.81 | CTSK (0.38) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15672769 | 0.78 | CA1 (0.36) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27578195 | 0.78 | CTSS (0.36) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27550061 | 0.78 | CTSS (0.36) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6116336 | 0.75 | CYP2C9 (0.35) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28376281 | 0.73 | NOS1 (0.33) | CTSSCTSKCYP2C9CYP2C19KMT2A | |
| SCHEMBL1344808 | 0.70 | KMT2A (0.39) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28710632 | 0.70 | KMT2A (0.39) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11432708 | 0.69 | MEN1 (0.36) | HTTMEN1GAAKMT2A | |
| SCHEMBL27640187 | 0.69 | CTSK (0.36) | CTSSCTSKMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | CTSS 1883/4885CTSK 1786/4885CYP1A2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.